Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin studies this year.

Sam Altman, the CEO of OpenAI, has announced a shift in his previously critical perspective on President Donald Trump. Newsweek has contacted OpenAI and the White House for comment via email.

Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT reports.

Though Altman said he likely wouldn’t agree with Trump on “everything,” the OpenAI CEO said he believes “he will be incredible for the country in many ways.”

OpenAI CEO Sam Altman took the technology world by surprise on Thursday with the release of Operator, his company's first AI agent that can act

Musk’s criticisms have escalated into legal actions. In February, he filed a lawsuit against OpenAI, accusing it of breaching its nonprofit mandate. Although the lawsuit was withdrawn in June, Musk refiled it in August, further intensifying the conflict.

"I genuinely respect your accomplishments and think you are the most inspiring entrepreneur of our time," Altman wrote in an X post to Musk.

Tensions between technology leaders Elon Musk and OpenAI CEO Sam Altman were on full display this week after the Tesla CEO slammed the new artificial intelligence (AI) infrastructure project,

The prime minister’s bumbling answer to a press club question on Australia’s engagement in the AI arms race shows how complacent political and business leaders are.

Chinese start-up DeepSeek is as powerful as ChatGPT and purportedly uses much less computing power. Will this competition spur US companies to greater things?

More orders are expected Tuesday amid fallout from his first moves, including his issuing pardons for more than a thousand rioters convicted in connection with the violent Jan. 6 attack on the U.S. Capitol and his effort to end birthright citizenship.